FOR UK HEALTHCARE PROFESSIONALS ONLY
For UK Healthcare Professionals Only

Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

  1. Home
  2. Atopic Dermatitis
  3. Type 2 inflammation

Management approaches in moderate-to-severe AD should address the persistent underlying Type 2 inflammation

  • Three types of immune response play a natural protective role against different pathogens, the Type 2 immune response drives AD specifically2-4
  • Broad spectrum immunosuppressants do not specifically inhibit Type 2 inflammatory pathway5-7
  • Non-specific mechanisms may result in unwanted side effects and the need for lab monitoring, limiting traditional systemic treatments as long-term therapeutic options2,5-10

IL-4 and IL-13 drive Type 2 inflammation

IL-4 and IL-13 are key Type 2 cytokines involved in the pathogenesis of AD2,4

EXPLORE KEY TYPE 2 CYTOKINES

DUPIXENT targets Type 2 inflammation

DUPIXENT inhibits IL-4 and IL-13 signalling, and reduces persistent underlying Type 2 inflammation in AD1,20

EXPLORE TARGETED APPROACH

DUPIXENT demonstrated a safety profile in clinical studies that is consistent in both adults and adolescents

  • DUPIXENT has a long-term safety and tolerability profile that has been investigated up to 3 years in clinical trials in adults1,21
  • The long-term safety profile seen in adults is consistent with the safety profile of adolescents in a 16-week, Phase 3 trial1,22
  • DUPIXENT does not require routine laboratory monitoring1

Inflammatory pathways

What are the main inflammatory pathways involved in the disease? Find out about the pathway involved in AD.

Find out more

Overview of AD

Find out more about how AD has a continuous inflammation cycle.

Find out more

Mode of action DUPIXENT

Have questions about how DUPIXENT works?

Find out more

AD, atopic dermatitis; IL, interleukin.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: December 2020.
  2. Leung DYM, et al. J Clin Invest. 2004;113(5):651–657.
  3. Suárez-Fariñas M, et al. J Allergy Clin Immunol. 2011;127(4):954–964.
  4. Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
  5. Hajar T, et al. An Bras Dermatol. 2018;93:104–107.
  6. Wakelin SH, et al. Medicine. 2017;45:363–367.
  7. Moyle M, et al. Exp Dermatol. 2019;28:756–768.
  8. Seegräber M, et al. Expert Rev Clin Pharmacol. 2018; 11:467–474.
  9. Armstrong AW, et al. PLoS ONE. 2019:14:e0210517.
  10. Wu J & Guttman-Yasky E. Expert Opin Biol Ther. 2020;20:525–538.
  11. Kaiko GE, et al. Immunol. 2008;123:326–338.
  12. Eyerich K & Eyerich S. J Eur Acad. 2017;32:692–703.
  13. Raphael I, et al. Cytokine. 2015;74:5–17.
  14. Schwartz DM, et al. Nat Rev Rheumatol. 2016;12(1):25–36.
  15. Murray PJ. J Immunol. 2007;178(5):2623–2629.
  16. Annunziato F, et al. J Allergy Clin Immunol. 2015;135(3):626–635.
  17. Schleimer R. Annu Rev Pathol. 2017;12:331–357.
  18. Nakayama T, et al. Annu Rev Immunol. 2017;35:53–84.
  19. Coates LC, et al. Semin Arthritis Rheum. 2016;46:291–304.
  20. Blauvelt A, et al. Lancet. 2017;389(10086):2287–2303.
  21. Thaçi D, et al. Favorable Safety and Sustained Efficacy With Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis up to 3 Years (LIBERTY AD OLE) presented at the 20th Annual Las Vegas Dermatology Seminar, Nevada, USA, November 7–9 2019.
  22. Paller A, et al. Am J Clin Derm. 2020;21(1): 119–131.